Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Human-specific elimination of epithelial Siglec-XII suppresses the risk of inflammation-driven colorectal cancers
Hector A. Cuello, Saptarshi Sinha, Andrea L. Verhagen, Nissi Varki, Ajit Varki, Pradipta Ghosh
Hector A. Cuello, Saptarshi Sinha, Andrea L. Verhagen, Nissi Varki, Ajit Varki, Pradipta Ghosh
View: Text | PDF
Research Article Inflammation Oncology

Human-specific elimination of epithelial Siglec-XII suppresses the risk of inflammation-driven colorectal cancers

  • Text
  • PDF
Abstract

Carcinomas are common in humans but rare among closely related “great apes.” Plausible explanations, including human-specific genomic alterations affecting the biology of sialic acids, are proposed, but causality remains unproven. Here, an integrated evolutionary genetics-phenome-transcriptome approach studied the role of SIGLEC12 gene (encoding Siglec-XII) in epithelial transformation and cancer. Exogenous expression of the protein in cell lines and genetically engineered mice recapitulated approximately 30% of the human population in whom the protein is expressed in a form that cannot bind ligand because of a fixed, homozygous, human-universal missense mutation. Siglec-XII–null cells/mice recapitulated the remaining approximately 70% of the human population in whom an additional polymorphic frameshift mutation eliminates the entire protein. Siglec-XII expression drove several pro-oncogenic phenotypes in cell lines and increased tumor burden in mice challenged with chemical carcinogen and inflammation. Transcriptomic studies yielded a 29-gene signature of Siglec-XII–positive disease and when used as a computational tool for navigating human data sets, pinpointed with surprising precision that SIGLEC12 expression (model) recapitulates a very specific type of colorectal carcinomas (disease) that is associated with mismatch-repair defects and inflammation, disproportionately affects European Americans, and carries a favorable prognosis. They revealed a hitherto-unknown evolutionary genetic mechanism for an ethnic/environmental predisposition of carcinogenesis.

Authors

Hector A. Cuello, Saptarshi Sinha, Andrea L. Verhagen, Nissi Varki, Ajit Varki, Pradipta Ghosh

×

Figure 1

Mechanism and observed prevalence of human-specific inactivation and elimination of the protein product of SIGLEC12.

Options: View larger image (or click on image) Download as PowerPoint
Mechanism and observed prevalence of human-specific inactivation and eli...
(A) Schematic (top) summarizes the impact of the human-universal mutation (rs16982743) of the gene SIGLEC12, which results in a loss of an essential arginine that abolishes the ability of the Siglec-XII protein to bind/recognize sialic acids (Sias). This functionally inactivating mutation occurred prior to the common ancestor of all modern humans. SIGLEC12 is intact and functional in great apes. Schematic (bottom) summarizes the ongoing selection for the Siglec-XII–null state that continues in the current worldwide human population. The most common polymorphic mutation is a frameshift mutation (rs66949844), guanine (G) insertion, which in the homozygous state eliminates the protein expression in most humans. (B) Pie charts indicate the restricted prevalence of Siglec-XII expression (~30%) in the entire human population (left) but the enrichment of such expressors among all (middle) and only colorectal (right) carcinomas.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts